Explicyte will attend the ASCO Annual Meeting in Chicago this June 2025.
Our CEO, Dr. Alban Bessède, will present two posters highlighting translational studies conducted in collaboration with leading academic and industry partners:
Alban will be available for 1:1 meetings during the event (June 1–3) to explore opportunities for collaborations in preclinical and translational research in precision oncology.
Our CEO, Dr. Alban Bessède, will present two posters highlighting translational studies conducted in collaboration with leading academic and industry partners:
- Spatial transcriptomics reveal crucial determinants of immune exclusion in non-small cell lung cancer From the Precision Medicine BIP Study In collaboration with GSK, Institut Bergonié, and Gustave Roussy
- CCR8⁺ regulatory T cells and their correlation with immunotherapy response in advanced NSCLC In collaboration with Bayer AG, Institut Bergonié, and Gustave Roussy
Alban will be available for 1:1 meetings during the event (June 1–3) to explore opportunities for collaborations in preclinical and translational research in precision oncology.
Book a 1:1 meeting
Alban Bessede, CEO of Explicyte, will attend the Meet2win oncology event in Bordeaux, France (May 6-7).
He will be available for 1:1 meetings over this 2-day event, to discuss potential preclinical and translational research opportunities.
He will be available for 1:1 meetings over this 2-day event, to discuss potential preclinical and translational research opportunities.
Alban Bessede, CEO, and Jean-Philippe Guegan, CTO, will present 2 posters at the 2025 AACR annual meeting in Chicago (April 25-30):
Feel free to reach out to them to arrange an on-site meeting!
- Impact of Immune Contexture on Immunotherapy Response in NSCLC: Insights from Multiplex IHC and Machine Learning-Based Phenotyping
- Tertiary Lymphoid Structures as Predictors of Immune Checkpoint Inhibitor Efficacy in NSCLC and the Development of an Ex Vivo Model for Precision Medicine
Feel free to reach out to them to arrange an on-site meeting!
Book a 1:1 meeting
Join us for an insightful session on March 27th, featuring the first authors behind three influential 2025 papers on tertiary lymphoid structures (TLS) in cancer:
Presenting a groundbreaking 2025 Nature paper, "IL-33-activated ILC2s induce tertiary lymphoid structures in pancreatic cancer". Dr. Amisaki’s work deepens our understanding of TLS biology and paves the way for innovative therapeutic strategies for transforming “cold” tumors into immunologically active environments.
Sharing findings from his PhD research, conducted at Explicyte, Dr. Peyaud will discuss 2 publications:
Immunologist Alban Bessede, PhD, CEO of Explicyte, will kick off the session. Dr Bessede has been working on TLS since 2020, co-authoring foundational papers in Nature Cancer and Nature Medicine on TLS & immune-checkpoint inhibitors, and is now developing accredited pathology services for detecting and scoring TLS in tumor specimens to support precision oncology initiatives.
Masataka Amisaki, MD, PhD, MSKCC (USA)
Presenting a groundbreaking 2025 Nature paper, "IL-33-activated ILC2s induce tertiary lymphoid structures in pancreatic cancer". Dr. Amisaki’s work deepens our understanding of TLS biology and paves the way for innovative therapeutic strategies for transforming “cold” tumors into immunologically active environments.
Florent Peyraud, MD, PhD, Institut Bergonié (France)
Sharing findings from his PhD research, conducted at Explicyte, Dr. Peyaud will discuss 2 publications:
- A research paper in Cell Reports Medicine titled "Spatially resolved transcriptomics reveal the determinants of primary resistance to immunotherapy in NSCLC with mature tertiary lymphoid structures"
- A comprehensive review in Med. titled "Tertiary lymphoid structures and cancer immunotherapy: From bench to bedside"
Session Introduction
Immunologist Alban Bessede, PhD, CEO of Explicyte, will kick off the session. Dr Bessede has been working on TLS since 2020, co-authoring foundational papers in Nature Cancer and Nature Medicine on TLS & immune-checkpoint inhibitors, and is now developing accredited pathology services for detecting and scoring TLS in tumor specimens to support precision oncology initiatives.
Register for the webinar
Imane Nafia, PhD, Chief Scientific Officer of Explicyte, will attend AACR IO in Los Angeles (Feb. 23-26).
Contact us to arrange a meeting on-site
Contact us to arrange a meeting on-site
Since 2021, Explicyte has developed a specific expertise in Tertiary Lymphoid Structure (TLS) detection and scoring by digital pathology. Hosted by Alban Bessede, PhD, CEO of Explicyte, this 45-minute webinar dedicated to TLS modulation in cancer immunotherapy will feature 2 presentations:
Following a PhD thesis on intratumoral T cells at Johns Hopkins in 2010, Tullia Bruno started working on the role of B cells in the TME during her postdoctoral fellowship at the University of Colorado Denver. In 2015, she joined the University of Pittsburgh as an Assistant Professor to investigate the role of intratumoral B cell function within TLS in solid tumors. Focused on translational research and the development of novel immunotherapies, she is also a faculty member in the Tumor Microenvironment Center and the Cancer Immunology and Immunotherapy Program at the UPMC Hillman Cancer Center.
Author of 500+ peer-reviewed publications, Pr. Italiano has been the Principal Investigator of 50+ clinical trials over the past 5 years, investigating the resistance mechanisms to cancer immunotherapies in solid tumors. Trained as a medical oncologist in France, he obtained a PhD in Molecular & Cell Biology in 2008. He then joined the laboratory of Cristina Antonescu for a post-doctoral fellowship at the MSKCC (New York, USA). He is currently leading Early Phase Trials and Sarcoma Units at Institut Bergonié (Bordeaux, France) and the head of the Precision Medicine unit at Gustave Roussy (Villejuif, France).
More about Explicyte's capacities for TLS detection & scoring in patient specimens
Tertiary lymphoid structures as modulators of anti-tumor immunity: what do we know and where are we headed?
Tullia C. Bruno, PhD - UPMC Hillman Cancer Center / University of Pittsburgh
Following a PhD thesis on intratumoral T cells at Johns Hopkins in 2010, Tullia Bruno started working on the role of B cells in the TME during her postdoctoral fellowship at the University of Colorado Denver. In 2015, she joined the University of Pittsburgh as an Assistant Professor to investigate the role of intratumoral B cell function within TLS in solid tumors. Focused on translational research and the development of novel immunotherapies, she is also a faculty member in the Tumor Microenvironment Center and the Cancer Immunology and Immunotherapy Program at the UPMC Hillman Cancer Center.
Predictive role of TLS for cancer immunotherapy: current insights and perspectives
Pr Antoine Italiano, MD, PhD - Institut Bergonié & Gustave Roussy Comprehensive Cancer Centers
Author of 500+ peer-reviewed publications, Pr. Italiano has been the Principal Investigator of 50+ clinical trials over the past 5 years, investigating the resistance mechanisms to cancer immunotherapies in solid tumors. Trained as a medical oncologist in France, he obtained a PhD in Molecular & Cell Biology in 2008. He then joined the laboratory of Cristina Antonescu for a post-doctoral fellowship at the MSKCC (New York, USA). He is currently leading Early Phase Trials and Sarcoma Units at Institut Bergonié (Bordeaux, France) and the head of the Precision Medicine unit at Gustave Roussy (Villejuif, France).
More about Explicyte's capacities for TLS detection & scoring in patient specimens
Register for the webinar
From the 8th to the 14th of September, Gregory Lebras will run 330km in the Aosta Valley, in Italy. Enlisted for the TOR330 - TOR DES GÉANTS ultra-endurance trail together with 1,100 competitors, this anesthetist nurse at the Institut Bergonié Comprehensive Cancer Center aims to raise funds to support sarcoma research. Over 7 days, he will encourage his audience to make donations to the not-for-profit association "La Course du Petit Prince".
"We actively participate in the RHU Condor, a research consortium that receives funds from "La Course du Petit Prince" for the development of novel immunotherapies against soft-tissue sarcoma. So when we learned about the initiative of Gregory, we felt compelled to be part of it. Gregory is currently running over 10h per week, he's dedicated, fun, and generous. It just clicked. I can tell we are very proud sponsors !" Alban Bessede, CEO of Explicyte.
https://youtu.be/ejnRb2Acr3Y?si=qovB7lJ2FTELxqxj
"We actively participate in the RHU Condor, a research consortium that receives funds from "La Course du Petit Prince" for the development of novel immunotherapies against soft-tissue sarcoma. So when we learned about the initiative of Gregory, we felt compelled to be part of it. Gregory is currently running over 10h per week, he's dedicated, fun, and generous. It just clicked. I can tell we are very proud sponsors !" Alban Bessede, CEO of Explicyte.
https://youtu.be/ejnRb2Acr3Y?si=qovB7lJ2FTELxqxj
Make a donation
Imane Nafia, Chief Scientific Officer at Explicyte, will attend the 39th Annual Meeting of the Society for Immunotherapy of Cancer - SITC (Houston USA, November 6-10, 2024) to share some new developments and translational research work. Her abstract title:
Ovarian cancer ascites exhibit an impaired immune environment - immunosuppressive & protumoral – detrimental to the immune response
Ovarian cancer ascites exhibit an impaired immune environment - immunosuppressive & protumoral – detrimental to the immune response
ASCO Annual Meeting ended last week! Back in France, our CEO, Alban Bessede shares with us his observations and thoughts on this year’s edition.
We are thrilled to announce that Explicyte will be attending the AACR annual meeting this year in Orlando, to share our latest developments and translational research works.
A new anti-PD1 resistant mouse sarcoma model, ovarian cancer ascites as a remarkable tool for translational research or our GeoMx platform to support your spatial transcriptomics programs... check out our best highlights of 2022!